Clinical Trial

Cera™ ASD Occluder Post-Market Clinical Follow-Up Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this post-market study is to: * collect real-word clinical data and confirm the long-time safety and performance of the Lifetech Cera™ ASD Occluder * identify previously unknown side-effects
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-25.
Trial Details
NCT Number NCT06849635
Lead Sponsor Lifetech Scientific (Shenzhen) Co., Ltd.
Conditions Atrial Septal Defect
Enrollment 139 participants
Start Date 2025-01-03
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-03-06